Oncology

Interfering with energetic metabolism may stop glioblastoma growth and recurrence.

Rehabilitation with the help of the internet ameliorates life quality and side effects in women with breast cancer.

Having multiple sclerosis may not increase the risk of breast cancer in women.

The proportion of cancer deaths attributable to smoking differs among states, but the highest proportion was seen in the Southern United States.

Top news of the day from across the health care landscape.

Total thyroidectomy is the most common treatment for thyroid cancer.

Ribociclib seeks approval as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

The FDA has accepted Novartis’ New Drug Application (NDA) and granted Priority Review for LEE011 (ribociclib).

A chemical inhibitor was found to limit the growth of lung tumor cells and may provide better treatment for lung cancer patients.

Stay up-to-date with the hottest news in pharmacy!

Tumor markers can help guide future treatments for patients with bladder cancer.

Top news of the week in oncology and cancer drug development.

Developed countries may be able to assist developing countries in ensuring their drugs are safe.

Top news of the day from across the health care landscape.

Testing method could improve radioembolization technique in cancer treatment.

Newly-discovered compound blocks an essential protein in sustaining tumor growth.

Keytruda approved as a first-line treatment for non-small cell lung cancer.

Swedish study suggests that more American men can opt surveillance over prostate cancer treatment.

Astellaas Pharma has entered into an agreement to acquire Ganymed and its investigational cancer antibodies.

Triolimus contains paclitaxel plus 2 agents to prevent chemotherapy resistance.

Injections of nanoliposomes reversed memory loss associated with Alzheimer’s disease in mouse models.

Top news of the day from across the health care landscape.

Eli Lilly and Company will launch a revised version of a tool that tracks the progress of cancer over time.

A specific mark in histones speeds up repairs in cancer cells, increasing their resistance to treatment.

Top news of the day from across the health care landscape.

A novel approach looks to provide researchers with the tools to make accurate and safe predictions for cancer patients.

Ribociclib treats patients with HR+/HER2- advanced or metastatic breast cancer.

Experimental drug treats patients with HR+/HER2- advanced or metastatic breast cancer.